CN104159894B - 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物 - Google Patents

作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物 Download PDF

Info

Publication number
CN104159894B
CN104159894B CN201380012764.6A CN201380012764A CN104159894B CN 104159894 B CN104159894 B CN 104159894B CN 201380012764 A CN201380012764 A CN 201380012764A CN 104159894 B CN104159894 B CN 104159894B
Authority
CN
China
Prior art keywords
alk
fak
day
cep
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380012764.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104159894A (zh
Inventor
劳伦特·库瓦西耶
马丁·J·雅各布斯
格雷戈里·R·奥特
肖恩·P·阿尔文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104159894(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Priority to CN201610591742.5A priority Critical patent/CN106166155B/zh
Publication of CN104159894A publication Critical patent/CN104159894A/zh
Application granted granted Critical
Publication of CN104159894B publication Critical patent/CN104159894B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CN201380012764.6A 2012-03-06 2013-03-06 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物 Active CN104159894B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610591742.5A CN106166155B (zh) 2012-03-06 2013-03-06 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
US61/607,305 2012-03-06
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610591742.5A Division CN106166155B (zh) 2012-03-06 2013-03-06 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物

Publications (2)

Publication Number Publication Date
CN104159894A CN104159894A (zh) 2014-11-19
CN104159894B true CN104159894B (zh) 2016-09-07

Family

ID=47892060

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610591742.5A Active CN106166155B (zh) 2012-03-06 2013-03-06 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物
CN201380012764.6A Active CN104159894B (zh) 2012-03-06 2013-03-06 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610591742.5A Active CN106166155B (zh) 2012-03-06 2013-03-06 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物

Country Status (28)

Country Link
US (5) US9132128B2 (OSRAM)
EP (2) EP2822939B1 (OSRAM)
JP (2) JP6016953B2 (OSRAM)
KR (1) KR102068374B1 (OSRAM)
CN (2) CN106166155B (OSRAM)
AU (1) AU2013229995B2 (OSRAM)
CA (1) CA2865420C (OSRAM)
CL (1) CL2014002353A1 (OSRAM)
CY (1) CY1117565T1 (OSRAM)
DK (1) DK2822939T3 (OSRAM)
EA (2) EA033124B1 (OSRAM)
ES (2) ES2681487T3 (OSRAM)
HR (1) HRP20160387T1 (OSRAM)
HU (1) HUE027976T2 (OSRAM)
IL (2) IL234239A (OSRAM)
ME (1) ME02460B (OSRAM)
MX (2) MX347772B (OSRAM)
MY (1) MY177290A (OSRAM)
NZ (1) NZ630251A (OSRAM)
PH (1) PH12014501979B1 (OSRAM)
PL (1) PL2822939T3 (OSRAM)
RS (1) RS54689B1 (OSRAM)
SG (2) SG11201405371PA (OSRAM)
SI (1) SI2822939T1 (OSRAM)
SM (1) SMT201600134B (OSRAM)
UA (1) UA115052C2 (OSRAM)
WO (1) WO2013134353A1 (OSRAM)
ZA (1) ZA201406147B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106166155A (zh) * 2012-03-06 2016-11-30 赛福伦公司 作为alk和fak双重抑制剂的稠合双环2,4‑二氨基嘧啶衍生物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
JP6849594B2 (ja) * 2014-12-23 2021-03-24 セファロン、インク． 縮合二環式２，４−ジアミノピリミジン誘導体を調整する方法
AU2019319109A1 (en) 2018-08-07 2021-02-25 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in cobination with anaplastic lymphoma kinase inhibitors
WO2024178339A2 (en) * 2023-02-23 2024-08-29 The Regents Of The University Of Michigan Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1918158A (zh) * 2004-02-14 2007-02-21 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101535276A (zh) * 2006-10-23 2009-09-16 赛福伦公司 作为ALK和c-MET抑制剂的2，4-二氨基嘧啶稠合双环衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
RU2395500C2 (ru) 2003-08-15 2010-07-27 Новартис Аг 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
WO2005097765A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
ES2622493T3 (es) * 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
EP3012249A1 (en) * 2006-12-08 2016-04-27 Novartis AG Compounds and composition as protein kinase inhibitors
ES2593486T3 (es) * 2007-04-18 2016-12-09 Pfizer Products Inc. Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
WO2010143664A1 (ja) * 2009-06-10 2010-12-16 中外製薬株式会社 ４環性化合物
CA2865420C (en) * 2012-03-06 2020-06-02 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
JP6849594B2 (ja) * 2014-12-23 2021-03-24 セファロン、インク． 縮合二環式２，４−ジアミノピリミジン誘導体を調整する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1918158A (zh) * 2004-02-14 2007-02-21 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101535276A (zh) * 2006-10-23 2009-09-16 赛福伦公司 作为ALK和c-MET抑制剂的2，4-二氨基嘧啶稠合双环衍生物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106166155A (zh) * 2012-03-06 2016-11-30 赛福伦公司 作为alk和fak双重抑制剂的稠合双环2,4‑二氨基嘧啶衍生物
CN106166155B (zh) * 2012-03-06 2019-01-18 赛福伦公司 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物

Also Published As

Publication number Publication date
EP2822939B1 (en) 2016-02-17
SI2822939T1 (sl) 2016-04-29
IL252364B (en) 2018-03-29
HUE027976T2 (en) 2016-11-28
CA2865420C (en) 2020-06-02
JP2015509540A (ja) 2015-03-30
MX2014010613A (es) 2014-09-18
KR102068374B1 (ko) 2020-01-20
MX347772B (es) 2017-05-12
MX372740B (es) 2020-05-04
CL2014002353A1 (es) 2015-01-09
EA025859B1 (ru) 2017-02-28
US20150011561A1 (en) 2015-01-08
DK2822939T3 (en) 2016-03-14
MY177290A (en) 2020-09-10
ES2681487T3 (es) 2018-09-13
EP3056494A1 (en) 2016-08-17
EA201691574A1 (ru) 2017-03-31
IL234239A (en) 2017-06-29
AU2013229995A1 (en) 2014-09-25
US20170173017A1 (en) 2017-06-22
NZ630251A (en) 2016-02-26
EP3056494B1 (en) 2018-05-02
JP6016953B2 (ja) 2016-10-26
CN104159894A (zh) 2014-11-19
SG10201507865QA (en) 2015-10-29
ES2570976T3 (es) 2016-05-23
SMT201600134B (it) 2016-07-01
CN106166155B (zh) 2019-01-18
HRP20160387T1 (hr) 2016-05-20
RS54689B1 (sr) 2016-08-31
US20190328735A1 (en) 2019-10-31
IL252364A0 (en) 2017-07-31
WO2013134353A8 (en) 2014-06-19
ZA201406147B (en) 2015-12-23
WO2013134353A1 (en) 2013-09-12
AU2013229995B2 (en) 2017-04-13
PH12014501979A1 (en) 2014-11-24
US10111872B2 (en) 2018-10-30
PH12014501979B1 (en) 2014-11-24
EA033124B1 (ru) 2019-08-30
HK1205119A1 (zh) 2015-12-11
US20160243119A1 (en) 2016-08-25
PL2822939T3 (pl) 2016-08-31
US10632119B2 (en) 2020-04-28
EA201491641A1 (ru) 2015-04-30
CN106166155A (zh) 2016-11-30
US9339502B2 (en) 2016-05-17
US9623026B2 (en) 2017-04-18
SG11201405371PA (en) 2014-09-26
UA115052C2 (uk) 2017-09-11
JP2017039741A (ja) 2017-02-23
CA2865420A1 (en) 2013-09-12
EP2822939A1 (en) 2015-01-14
ME02460B (me) 2017-02-20
HK1226300A1 (zh) 2017-09-29
KR20140138247A (ko) 2014-12-03
US9132128B2 (en) 2015-09-15
US20150374693A1 (en) 2015-12-31
CY1117565T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
CN104159894B (zh) 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物
CN105311030B (zh) 用于抗肿瘤的螺取代化合物
JP6674586B2 (ja) 血液脳関門通過能を有する置換キナゾリン化合物
CN111107851B (zh) 组合及其用于治疗癌症的用途
KR20170097651A (ko) 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
KR102685187B1 (ko) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
HK1226300B (zh) 作为alk和fak双重抑制剂的稠合双环2，4-二氨基嘧啶衍生物
HK1226732B (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
HK1205119B (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
TWI570116B (zh) 取代的吡唑酮化合物及其使用方法
CN105829303A (zh) 作为离子通道调节剂的稠合杂环化合物
HK40011011A (en) Cannabinoid receptor modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant